Quoting the spruiker:The seasonal sales of Relenza have never...

Quoting the spruiker:
The seasonal sales of Relenza have never been strong, however LANI could change this especially with a Japanese Pharma marketing it to their domestic market.

Differentiating the Spruik from Facts:
LANI has not completed all the testing and has yet to be licensed for use anywhere in the world.


Quoting the spruiker:
Stockpiling continues to be a massive market. The UK order proves that governments are very concerned about a possible mutation of the H5N1 virus or other possible pandemic bug. The order also illustrates the move to Relenza.

Differentiating the Spruik from Facts:
For the first half of this FY, Biota announced Relenza royalties is a miserable $3.4 million ($1.9m in the 1Q falling to $1.5m in 2Q), perhaps just enough to pay the Christmas bonuses and partying. The UK order lacks details of funding – could be over 1 year, 2 years, or 3 years, no body knows. EVEN IF in the extreme event that ALL the order is delivered between now and 30 June, the Relenza royalties will still fall FAR SHORT of the $30 million spruiked on some brokers report.

Quoting the spruiker:
At the current price BTA is trading around cash backing
and
I'd also recommend the directors have another look at buy backs. What better time to buy back your shares than now?
and
BTA in my opinion should not pay a dividend. If anything it should recommence the on market buy back with it's cash balance. It could buy back 20-30% of stock and still have more than enough cash and future income to fund a pipeline”

Facts:
The poor sod has NO IDEA what the cash backing is and making statements that BTA is trading around cash backing reflect the nonsense he is capable of posting to spruik BTA! Biota made a loss last year and then Peter Cook blamed it on the previous CEO Peter Molloy for suing GSK. When BTA is not even making a profit, talking about paying dividend is pure flatulation.

Biota announced in the AGM a $55M cash backing at the end of September which equates to 31.5 cents. BUT since 30 September, Biota had spent $15 million on the HRV trials to 31 Jan 09; embark on a company shares buyback and increased board size. The only income known to come in after 30 September is the $4.2m from AstraZeneca and the miserable Relenza royalties. Biota is estimated to burn between $4million to $5 million a month. By the most conservative estimate, the cash backing had peaked at $55m and falling rapidly. The first half results to be released will soon may reveal the real situation.